In traditional DBS, a battery pack externally sends electrical signals through wires, activating nerve cells in a region of the brain called the subthalamic nucleus (STN). STN activation can relieve motor symptoms of Parkinson’s disease, including tremors, slowness, rigidity and involuntary movements. However, because the potential side effects, including brain hemorrhage and tissue damage, can be severe, DBS is usually reserved for people who have late-stage Parkinson’s disease or when symptoms are no longer manageable with medication. In a step toward a less invasive treatment, Minsuk Kwak and Jinwoo Cheon worked with their colleagues to develop a wireless method to effectively reduce motor dysfunction in people with Parkinson’s disease.
For their wireless technique, the researchers tagged nanoscale magnets with antibodies to help the molecules “stick” to the surface of STN nerve cells. Then they injected the sticky magnets into the brains of mice with early- and late-stage Parkinson’s disease. Prior to the injection in the STN, those same nerve cells had been modified with a gene that caused them to activate when the modified magnets on the cell’s surface twisted in reaction to an externally applied magnetic field of about 25 milliteslas, which is about one- thousandth the strength of an MRI.
In demonstrations of the magnetized and modified neurons in mice with Parkinson’s disease, the mice exposed to a magnetic field showed improved motor function to levels comparable to those of healthy mice. The team observed that mice that received multiple exposures to the magnetic field retained more than one-third of their motor improvements while mice that received one exposure retained almost no improvements. Additionally, the nerve cells of treated mice showed no significant damage in and around the STN, which suggests this could be a safer alternative to traditional implanted DBS systems, the researchers say. The team believes its wireless magnetogenetic approach has therapeutic potential and could be used to treat motor dysfunction in people with early- or late-stage Parkinson’s disease as well as other neurological disorders, such as epilepsy and Alzheimer’s disease.
Read the original article on American Chemical Society (ACS).
